louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03481530: Role of CGMS Usage in Predicting Risk for Hypoglycemia
Official title: Development of Novel Predictors of Hypoglycemia for Type 2 Diabetes: Role of CGMS Usage in Predicting Risk for Hypoglycemia
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Type 2 Diabetes Mellitus
Hypoglycemia
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2018-03-29
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adults with type 2 diabetes

Brief summary: This is a clinical study to examine rates hypoglycemia (self-report, EHR review, and review of values from a FDA approved continuous glucose monitoring system (CGMS)). Subjects will wear either blinded or unblinded CGMS. This is a 1:1 assignment with one group (50%) wearing 1 unblinded/1 blinded CGMS and the other group 50% wearing 2 blinded CGMS. The assignment will be computer based in a random fashion. Participants will continue with their usual diabetes management and glycemic monitoring profile as per usual. Those assigned to an unblinded CGMS can use the CGMS to manage their glucose levels at their own discretion. Individuals recruited will be those Type 2 diabetes who are deemed to be at high risk for hypoglycemia or low risk for hypoglycemia from a point score system established in an affiliated study.


Eligibility criteria: Inclusion Criteria:

* Type 2 Diabetes
* 18 years or older

Exclusion Criteria:

* Type 1 diabetes
* Current pregnancy or anticipation of pregnancy during study period
* At screening visit, HR\> 130 or SBP\>160 or DBP\>100 which remains present on recheck

Primary outcomes:
measure: Hypoglycemia rate
timeFrame: Week 16
Secondary outcomes:
measure: Comparison hypoglycemia rate
timeFrame: Week 16
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
References:
citation: Olawsky E, Zhang Y, Eberly LE, Helgeson ES, Chow LS. A New Analysis Tool for Continuous Glucose Monitor Data. J Diabetes Sci Technol. 2022 Nov;16(6):1496-1504. doi: 10.1177/19322968211028909. Epub 2021 Jul 20.
Clinical trial NCT02981030: Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine
Official title: Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine: A Demonstration Study of 800 mcg Buccal Misoprostol Following 200 mg Mifepristone for Abortion up to 70 Days Gestation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Abortion, Therapeutic
Lead sponsor: Gynuity Health Projects
Sponsor class: OTHER
Collaborators: name: Charitable Foundation Women Health & Family Planning
First posted: 2016-12-02
Enrollment: 102
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The study will examine how a simplified outpatient medical abortion procedure using mifepristone and misoprostol, with the option to take mifepristone at a place of woman's choosing, works in Ukraine. The investigators intend to demonstrate the efficacy of oral administration of 200 mg mifepristone and buccal administration of 800 mcg misoprostol with gestations through 70 days, as well as the acceptability of this method.


Eligibility criteria: Inclusion Criteria:

* Have an intrauterine pregnancy consistent with gestational age less than 71 days;
* Be able to understand and willing to sign a consent form;
* Be eligible for medical abortion according to the clinician's assessment;
* Be able to return to the clinic and able to contact study staff or emergency medical services, if needed;
* Be willing to provide an address and/or telephone number for purposes of follow-up;
* Agree to comply with the study procedures and visit schedule.

Exclusion Criteria:

* Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;
* Chronic renal failure;
* Concurrent long-term corticosteroid therapy;
* History of allergy to mifepristone, or misoprostol or another prostaglandin;
* History of hemorrhagic disorders or concurrent anticoagulant therapy;
* History of inherited porphyrias;
* Intrauterine device in place (must be removed before mifepristone is administered).

Primary outcomes:
measure: Rate of successful abortion
timeFrame: 2 weeks after mifepristone administration
Secondary outcomes:
Other outcomes:
Locations:
city: L'viv
country: Ukraine
facility: Lviv Municipal Women's Consultation No. 2
city: Vinnitsa
country: Ukraine
facility: Vinnitsa Regional Clinical Hospital
Study officials:
affiliation: Gynuity Health Projects
name: Ingrida Platais, MS
role: PRINCIPAL_INVESTIGATOR
affiliation: Gynuity Health Projects
name: Tamar Tsereteli, MD, MSc, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Gynuity Health Projects
name: Beverly Winikoff, MD, MPH
role: PRINCIPAL_INVESTIGATOR
affiliation: Charitable Foundation Women Health & Family Planning
name: Galyna Maystruk, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05623930: Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in Fatty Liver
Official title: Hepatic Enzymes and Metabolic-Risk Factors Responses to Laser Acupuncture Versus Cupping Therapy in Fatty Liver
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Fatty Liver
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2022-11-21
Enrollment: 60
Sex: ALL
Minimum age (years): 35
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)

Detailed description: In fatty liver patients,applied cupping (with scarification) will be compared, regarding its effect on antioxidant, lipid metabolism, cardioautonomic functions, and blood measures (glucose, inflammatory markers, liver enzymes), to application of laser on acupoints

Eligibility criteria: Inclusion Criteria:

* fatty liver obese patients

Exclusion Criteria:

thoracic diseases heart diseases kidney diseases

Primary outcomes:
measure: high density lipoprotein
timeFrame: 12 weeks
Secondary outcomes:
measure: cholesterol
timeFrame: 12 weeks
measure: low density lipoprotein
timeFrame: 12 weeks
measure: triglycerides
timeFrame: 12 weeks
measure: blood glucose
timeFrame: 12 weeks
measure: C reactive protein
timeFrame: 12 weeks
measure: Malondialdehyde
timeFrame: 12 weeks
measure: aspartate transaminase
timeFrame: 12 weeks
measure: alanine transaminase
timeFrame: 12 weeks
measure: systolic blood pressure
timeFrame: 12 weeks
measure: diastolic blood pressure
timeFrame: 12 weeks
measure: pulse rate
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo Unoversity
Study officials:
affiliation: Cairo University
name: Ali Ismail, lecturer
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01946230: The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma
Official title: The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Oral Potentially Malignant Disorder
Oral Cancer
Malignant Disorder
p62/SQSTM1
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2013-09-19
Enrollment: 2000
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Doctor of Dental Surgery

Brief summary: The mortality rate of oral cancer in Taiwan is still high with no decrease. One of the reasons result in these situations is the patent visits hospital for treatment in late stage of oral cancer. Recently, the government makes effort in oral cancer screening to find oral potentially malignant disorders (OPMD) early. However, there is no conscience in treatment strategies of OPMD up to now. In this study, we will set a OPMD data bank, and use the cases to find out the potential biomarker, which is able to predict the oral cancer malignant transformation. Sixty OPMD with oral cancer transformation will be recruited, and 60 OPMD with no oral cancer malignant transformation will also be enrolled as the disease control group. Besides, 20 normal cases and 60 oral cancer cases resulting from previous OPMD will be collected. All those groups will detect the expression of p62/SQSTM1 to investigate the possibility that p62/SQSTM1 as a biomarker to predict the malignant transformation of OPMM, and a guideline to treat or not to treat OPMD.


Eligibility criteria: Inclusion Criteria:

Study group was oral precancerous lesions in patients with malignant transformation; control group was generally no precancerous disease and orthodontic surgery volunteer

Exclusion Criteria:

Oral mucosa of subjects is too thin

Primary outcomes:
measure: The study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma
timeFrame: two year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: National Taiwan University Hospital
name: Chen Hsin Ming, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03359330: Mid-term Effect Observation of Biodegradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
Official title: A Multi-center Study on Mid-term Effect Observation of Biodegradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Peripheral Nerve Injuries
Keywords: Peripheral nervous system diseases
Wounds and injuries
Nerve regeneration
Biocompatible materials
Surgical procedures
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2017-12-02
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with fresh peripheral nerve injury in the upper extremities, requiring surgery

Brief summary: To observe the Mid-term clinical effect of biodegradable conduit small gap tublization to repair peripheral nerve injury in multi-center．

Detailed description: In the study，150 cases of fresh peripheral nerve injury in the upper extremities are recruited in multi-center． After formally informed and obtaining the consent，the biodegradable conduit small gap tublization are used to repair the nerve．Their nerve functional recovery conditions are clinically observed according to the standard score methods provided by SHEN Ning-jiang and British Medical Research Council at 3 years after surgery．The excellent and good rates of the overall nerve functional recovery are calculated．

Eligibility criteria: Inclusion Criteria:

* fresh peripheral nerve injury in the upper extremities

Exclusion Criteria:

* acute myocardial infarction history within 6 months,
* old and pathological peripheral nerve injury,
* acute and chronic infection,
* various consumptive diseases
* unable to tolerate surgery

Primary outcomes:
measure: Nerve function 1
timeFrame: 3 years after surgery
Secondary outcomes:
measure: Nerve function 2
timeFrame: 3 years after surgery
Other outcomes:
Locations:
Study officials:
affiliation: Department of orthopaedics and trauma
name: Peixun Zhang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04548830: Safety of Lung Cryobiopsy in People With Cancer
Official title: Safety of Transbronchial Cryobiopsy in a Cancer Population
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Lung Cancer
Keywords: Cryobiopsy
20-374
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2020-09-16
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This is a single center investigator initiated study for patients who display indeterminant pulmonary nodules and diffuse parenchymal lung disease on CT chest imaging who have been referred to the Pulmonary service.
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to find out whether a biopsy technique called transbronchial cryobiopsy (TBCB) is a safe alternative to the standard biopsy procedure (transbronchial forceps biopsy; TBFB). The study researchers think that TBCB may provide better biopsy samples to help diagnose lung disease.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or greater
* Patients with known or suspected diagnosis of cancer and indeterminant pulmonary nodules or diffuse parenchymal lung disease with non-diagnostic clinical profiles for whom a lung biopsy is deemed useful for diagnosis.

Exclusion Criteria:

* Patients with pulse oximetry less than 92% on oxygen delivery up to 2 L nasal cannula.
* Uncorrectable coagulopathy defined as:

  * Platelet count \<50,000 x 10\^9/L or
  * prothrombin time international normalized ratio \>1.5
* Known pulmonary hypertension or echocardiographic pulmonary artery systolic pressure \>50mmHg
* A secure diagnosis based on clinical and high-resolution CT scan data.
* Antiplatelet therapy that cannot be held for more than 5 days.
* Any patient deemed unfit to undergo bronchoscopy by the proceduralist
* Female patients with a positive pregnancy test within 30 days of the planned study procedure

Primary outcomes:
measure: Post Cryobiopsy complications
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center (All Protocol Activities)
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Or Kalchiem-Dekel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04336657: Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?
Official title: COVID-19-Like Illness: Did we Have Unusual Severe Respiratory Tract Infections October-December 2019 Before WHO Announcement ?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19
Keywords: COVID-19
Corona-like illness
WHO announcement
Survey
IgG
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-04-07
Enrollment: 100
Sex: ALL
Minimum age (years): 8
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The survey will be distributed online in English and Arabic and all responders well be included

Brief summary: A pneumonia of unknown cause detected in Wuhan, China was first reported to the WHO Country Office in China on 31 December 2019. The outbreak was declared a Public Health Emergency of International Concern on 30 January 2020. The spread and severity of the disease is variable from one country to another. Our team as well as many reports suggested that in some countries a " Flu like illness but much worse" was described in October, November and early in December before the WHO announcement. Was it COVID-19?


Eligibility criteria: Inclusion Criteria:

* All subject except excluded group

Exclusion Criteria:

* subject diagnosed as COVID-19 positive and their contacts

Primary outcomes:
measure: Measure frequency of people suffered from unusual flu-like symptoms before December 2019
timeFrame: one month
Secondary outcomes:
measure: Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible
timeFrame: 3 month
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: AssiutU
Study officials:
References:
Clinical trial NCT02099357: Creatine or Vitamin D Supplementation in Persons With Spinal Cord Injury Undergoing Resistance Training
Official title: Creatine or Vitamin D Supplementation in Persons With Spinal Cord Injury Undergoing Resistance Training
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Spinal Cord Injuries
Lead sponsor: Universidade do Porto
Sponsor class: OTHER
First posted: 2014-03-28
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine the effects of creatine monohydrate or vitamin D supplementation on strength gains following a traditional resistance training program for adults with spinal cord injury.


Eligibility criteria: Inclusion Criteria:

* Spinal cord injury
* Minimum time since injury: 3 months

Exclusion Criteria:

* Participation in resistance training programmes in the previous 6 months
* Creatine or vitamin D supplementation in the previous 6 months

Primary outcomes:
measure: Body Mass Index
timeFrame: 8 weeks
measure: Sum of 4 skinfold
timeFrame: 8 weeks
measure: Corrected Arm Muscle Area
timeFrame: 8 weeks
measure: Seated Medicinal Ball Throw
timeFrame: 8 weeks
measure: Handgrip Strength with Hand Dynamometer
timeFrame: 8 weeks
measure: Manual Wheelchair Slalom Test
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Cantanhede
country: Portugal
facility: Centro de Medicina de Reabilitação da Região Centro - Rovisco Pais
state: Coimbra
city: Vila Nova de Gaia
country: Portugal
facility: Centro de Reabilitação do Norte
state: Porto
Study officials:
affiliation: Faculdade de Ciências da Nutrição e Alimentação, Universidade do Porto
name: Vitor H Teixeira, PhD
role: STUDY_DIRECTOR
affiliation: Faculdade de Desporto, Universidade do Porto
name: Rui Corredeira, PhD
role: STUDY_CHAIR
affiliation: Faculdade de Desporto, Universidade do Porto
name: Samuel Amorim, Bsc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00826657: Vitamin B12 Supplementation Study
Official title: Assessment of Functional Vitamin B12 Deficiency in Mexican Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Vitamin B12 Deficiency
Keywords: B12 deficiency
methylmalonic acid
homocystein
vitamin B12 supplementation intervention
Lead sponsor: USDA, Western Human Nutrition Research Center
Sponsor class: FED
First posted: 2009-01-22
Enrollment: 180
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: We hope to learn the clinical and functional signs of sub-clinical vitamin B12 deficiency and its response to supplementation in non-anemic, non-pregnant, and non-lactating women in Rural Mexico. Vitamin B12 is important in hematopoiesis, neuro-cognitive functions and genetic integrity. However vitamin B12 is only found in animal source foods therefore a large segment of the population in developing countries and those practicing vegetarianism are at risk of deficiency of the vitamin. This information will help decide weather supplementation with vitamin B12 is necessary in such populations for public health reasons.


Eligibility criteria: Inclusion Criteria:

* Women age 20-59, apparently healthy, no severe B12 deficiency

Exclusion Criteria:

* pregnancy, lactation, anemia and disease states

Primary outcomes:
measure: response to B12 supplementation in serum B12, Methylmalonic acid, homocystein, and holotranscobalamin concentrations
timeFrame: 0 and 3 mos
Secondary outcomes:
measure: DNA methylation change, and hematological response to B12 supplementation
timeFrame: 0 and 3 mos
Other outcomes:
Locations:
city: Queretaro
country: Mexico
facility: Universidad Autonoma de Queretaro
Study officials:
References:
citation: Shahab-Ferdows S, Anaya-Loyola MA, Vergara-Castaneda H, Rosado JL, Keyes WR, Newman JW, Miller JW, Allen LH. Vitamin B-12 supplementation of rural Mexican women changes biochemical vitamin B-12 status indicators but does not affect hematology or a bone turnover marker. J Nutr. 2012 Oct;142(10):1881-7. doi: 10.3945/jn.112.165712. Epub 2012 Aug 22.
Clinical trial NCT03525457: Response to Periodontal Therapy in a Chronic Kidney Disease Population
Official title: Response to Non Surgical Periodontal Therapy in a Chronic Kidney Disease Population Candidates to Kidney Transplant
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Kidney Disease Stage 5
Periodontal Disease
Keywords: Glomerular filtration rate
Periodontitis
Chronic kidney disease
Lead sponsor: Pontificia Universidad Catolica de Chile
Sponsor class: OTHER
First posted: 2018-05-15
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate periodontal and systemic parameters of a cohort of chronic kidney disease (stage 5) patients, before and three months after non-surgical periodontal treatment. It does not consider a control group.

Detailed description: Dental biofilm is a source of inflammation and infection of periodontal tissues. In the last 20 years the interaction between periodontal infections and systemic conditions has been largely studied, suggesting that the inflammation caused in the periodontal tissues could cause a response in other parts of the body.

Recent studies suggest that there could be an association between periodontal disease and chronic kidney disease.

Eligibility criteria: Inclusion Criteria:

* Chronic kidney disease patients in Stage 5 (candidates to renal transplant)

Exclusion Criteria:

* Younger than 18 year old.

Primary outcomes:
measure: Change in Clinical Attachment Level (CAL)
timeFrame: 3 months
Secondary outcomes:
measure: Change in Bleeding on probing (BOP)
timeFrame: 3 months
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Clínica Odontológica Docente UC
state: Región Metropolitana
Study officials:
affiliation: Pontificia Universidad Catolica de Chile
name: Maite C Souyet, MsC
role: PRINCIPAL_INVESTIGATOR
References:
citation: Almeida S, Figueredo CM, Lemos C, Bregman R, Fischer RG. Periodontal treatment in patients with chronic kidney disease: a pilot study. J Periodontal Res. 2017 Apr;52(2):262-267. doi: 10.1111/jre.12390. Epub 2016 May 2.
citation: Graziani F, Cei S, La Ferla F, Vano M, Gabriele M, Tonetti M. Effects of non-surgical periodontal therapy on the glomerular filtration rate of the kidney: an exploratory trial. J Clin Periodontol. 2010 Jul;37(7):638-43. doi: 10.1111/j.1600-051X.2010.01578.x. Epub 2010 May 25.
citation: Chambrone L, Foz AM, Guglielmetti MR, Pannuti CM, Artese HP, Feres M, Romito GA. Periodontitis and chronic kidney disease: a systematic review of the association of diseases and the effect of periodontal treatment on estimated glomerular filtration rate. J Clin Periodontol. 2013 May;40(5):443-56. doi: 10.1111/jcpe.12067. Epub 2013 Feb 21.
citation: Limeres J, Garcez JF, Marinho JS, Loureiro A, Diniz M, Diz P. Early tooth loss in end-stage renal disease patients on haemodialysis. Oral Dis. 2016 Sep;22(6):530-5. doi: 10.1111/odi.12486. Epub 2016 May 27.